FormDescriptionFiling DateDownload
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]September 8, 2022
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]September 7, 2022
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]August 30, 2022
20FAnnual ReportAugust 15, 2022
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]May 20, 2022
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]May 19, 2022
6-KReport of foreign issuer [Rules 13a-16 and 15d-16]May 18, 2022
424B4Prospectus [Rule 424(b)(4)]May 18 2022
EFFECTNotice of EffectivenessMay 16, 2022
FWPFiling under Securities Act Rules 163/433 of free writing prospectusesMay 13, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentMay 13, 2022
CERTForm – CERTMay 12, 2022
8-A12BRegistration of securities [Section 12(b)]May 10, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentMay 9, 2022
F-6Registration of American Depository Receipt shares, not immediately effectiveMay 5, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentMay 4, 2022
FWPFiling under Securities Act Rules 163/433 of free writing prospectusesApril 29, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentApril 26, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentApril 14, 2022
F-1/ARegistration statement for certain foreign private issuers – amendmentMarch 25, 2022
F-1Registration statement for certain foreign private issuersMarch 4, 2022
DRS/ADraft Registration Statement – amendmentNovember 10, 2021
DRSDraft Registration StatementAugust 23, 2021
DRS/ADraft Registration Statement – amendmentMay 21, 2021
DRSDraft Registration StatementMarch 22, 2021

OKYO Pharma is listed on the NASDAQ and London Stock Exchange.

Stock information provided by TradingView. Minimum 15 minute delay.

Securities in Issue

OKYO Pharma issued share capital consists of 1,415,040,468 ordinary shares of no par value.

Percentage of shares not in public hands is approximately 39.16%

Holdings of Significant Shareholders

As of 24 May 2022 OKYO Pharma is aware of the following persons who hold, directly or indirectly, voting rights representing 5% or more of the issued share capital of OKYO Pharma to which voting rights are attached:

Name

Panetta Partners Limited

Number of shares

521,028,862

Percentage of issued share capital

36.82%

These shareholdings may differ from those shown on external electronic platforms, which are based solely on shareholder disclosures, because (i) fund managers may hold shares in multiple separate funds where part holdings are considered below disclosure requirement levels, (ii) fund managers may not hold all of the voting rights of the shares and (ii) external electronic platforms may not be up-to-date with new shareholder positions.

OKYO Pharma has appointed Computershare Investor Services (Guernsey) Limited as its Registrar. They are responsible for keeping the company’s register of shareholders up to date, distributing statutory documents such as the annual report and financial statements, and administering the payment of dividends.

If you have a query regarding your shareholding, please contact Computershare. If you wish to notify Computershare of a change of details or require a form regarding the transfer of shares, you can obtain downloadable forms from the Computershare website.

The Registrar

Computershare Investor Services (Guernsey) Limited
1st Floor
Tudor House
Le Bordage
St Peter Port
Guernsey GY1 1DB

Telephone: 0870 707 4040

Shareholders link to Forms including Change of Address.

You can also check your shareholding via the Computershare website.

Corporate Governance

Corporate Governance Code

As a Guernsey registered Company, OKYO Pharma is not under an obligation to adopt a Governance Code on a ‘comply or explain’ basis. However, given its status as a standard listed company on the main market for listed securities of the London Stock Exchange plc, the Directors recognise the importance of sound corporate governance and have opted to comply with QCA Corporate Governance Code, as published by the Quoted Companies Alliance, to the extent they consider appropriate in light of the Company’s size, stage of development and resources.

OKYO Pharma will hold Board meetings periodically as issues arise which require the Board’s attention. The Board will be responsible for the management of the business of OKYO Pharma, setting its strategic direction, establishing its policies and appraising the making of all material investments. It will be the Board’s responsibility to oversee the financial position of OKYO Pharma and monitor the business and affairs of OKYO Pharma on behalf of the shareholders, to whom the directors are accountable. The primary duty of the Board will be to act in the best interests of OKYO Pharma at all times. The Board will also address issues relating to internal control and OKYO Pharma’s approach to risk management.

OKYO Pharma has established an Audit Committee, a Remuneration Committee and a Nomination Committee of the Board with formally delegated duties and responsibilities.

  • Audit Committee meets not less than three times a year. The committee is responsible for making recommendations to the Board on the appointment of auditors and the audit fee and for ensuring that the financial performance of OKYO Pharma is properly monitored and reported. In addition, the Audit Committee receives and reviews reports from management and the auditors relating to the interim report, the annual report and accounts and the internal control systems of OKYO Pharma.
  • Remuneration Committee is responsible for the review and recommendation of the scale and structure of remuneration for senior management, including any bonus arrangements or the award of share options with due regard to the interests of the OKYO Pharma’s shareholders and the performance of OKYO Pharma.
  • Nomination Committee is responsible for reviewing succession plans for the directors, including the Executive Chairman, and Senior Management.

Share Dealing Code

The Board has adopted a code for dealings in OKYO Pharma’s securities by Directors or applicable employees which contains provisions appropriate for a company whose shares are admitted to trading on the Official List.

OKYO Pharma will take all reasonable steps to ensure compliance by the Directors and any applicable employees with the terms of that share dealing code.

Takeover Code

OKYO Pharma is subject to the UK City Code on Takeovers and Mergers (the “Takeover Code”) as it is incorporated in Guernsey. As a result, a takeover of OKYO Pharma and certain stake-holding activities of a shareholder are governed by the Takeover Code. The Takeover Code obliges a person or persons acquiring at least 30 per cent. of voting rights in a company to which the Takeover Code applies to make an offer to acquire the rest of the voting rights.

Corporate Documents

Corporate Information

The names of the directors and biographical details

Please click on the link below for the names and brief biographical details of each director.

Directors

Directors’ responsibilities

Please click on the link below for details on the directors’ responsibilities.

Corporate Governance

Board committees

Please click on the link below for details of OKYO Pharma’s Board committees.

Corporate Governance

Advisers

Please click on the link below for details of OKYO Pharma’s key advisers.

Corporate Directory

Country of incorporation and main country of operation

OKYO Pharma is incorporated and registered in Guernsey with company number 65220. OKYO Pharma’s main country of operation is the United Kingdom. Please click on the link below for the Memorandum and the Articles of Association.

Corporate Documents

Company announcements

Please click on the link below to access notifications made by OKYO Pharma in the past 12 months.

News

Details of any other exchanges or trading platforms

OKYO Pharma is not listed on any other exchanges or trading platforms.

Number of securities in issue

Please click on the link below for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as OKYO Pharma is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders.

Share Information

Details of any restrictions on the transfer of securities

There are no restrictions on the transfer of securities.

Financial information

Please click on the link below for access to OKYO Pharma’s annual and interim reports.

Corporate Documents

Admission documents and circulars

Please click on the appropriate links below to access:

Corporate Documents

ISIN

Please note that OKYO Pharma’s ISIN number is GG00BD3FV870.

Corporate Directory

Registered Office

OKYO Pharma Limited
Martello Court
Admiral Park
St. Peter Port
Guernsey GY1 3HB

Principle Trading Address

55 Park Lane
London W1K 1NA

Auditors

Mazars LLP
30 Old Bailey
London EC4M 7AU

Solicitors to the Company

Orrick, Herrington & Sutcliffe (UK) LLP
107 Cheapside
London EC2V 6DN

Registrar

Computershare Investor Services (Guernsey) Limited
1st Floor
Tudor House
Le Bordage
St. Peter Port
Guernsey GY1 1DB

Broker

Optiva Securities Limited
49 Berkeley Square
Mayfair
London W1J 5AZ